PL376536A1 - Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego - Google Patents

Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego

Info

Publication number: PL376536A1
Authority: PL; Poland
Prior art keywords: antagonists; cardiovascular disease; methods; treating cardiovascular; compositions
Prior art date: 2002-08-28

Application number

PL376536A

Other languages

English (en)

Inventor

Paul B. Burton

Theresa A. Deisher

Original Assignee

Immunex Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-28

Filing date

2003-08-21

Publication date

2006-01-09

2003-08-21 Application filed by Immunex Corporation filed Critical Immunex Corporation

2006-01-09 Publication of PL376536A1 publication Critical patent/PL376536A1/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Pulmonology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL376536A 2002-08-28 2003-08-21 Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego PL376536A1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US40641802P	2002-08-28	2002-08-28
US49445703P	2003-08-12	2003-08-12

Publications (1)

Publication Number	Publication Date
PL376536A1 true PL376536A1 (pl)	2006-01-09

Family

ID=31981396

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL376536A PL376536A1 (pl)	2002-08-28	2003-08-21	Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego

Country Status (8)

Country	Link
US (3)	US20040136992A1 (pl)
EP (1)	EP1545578A4 (pl)
JP (1)	JP2006508056A (pl)
AU (1)	AU2003259995B2 (pl)
CA (1)	CA2496795C (pl)
MX (1)	MXPA05002219A (pl)
PL (1)	PL376536A1 (pl)
WO (1)	WO2004019866A2 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8257428B2 (en)	1999-08-09	2012-09-04	Cardiokinetix, Inc.	System for improving cardiac function
US8529430B2 (en)	2002-08-01	2013-09-10	Cardiokinetix, Inc.	Therapeutic methods and devices following myocardial infarction
US8377114B2 (en)	1999-08-09	2013-02-19	Cardiokinetix, Inc.	Sealing and filling ventricular partitioning devices to improve cardiac function
US7674222B2 (en)	1999-08-09	2010-03-09	Cardiokinetix, Inc.	Cardiac device and methods of use thereof
US9694121B2 (en)	1999-08-09	2017-07-04	Cardiokinetix, Inc.	Systems and methods for improving cardiac function
US8500795B2 (en)	1999-08-09	2013-08-06	Cardiokinetix, Inc.	Retrievable devices for improving cardiac function
US10307147B2 (en)	1999-08-09	2019-06-04	Edwards Lifesciences Corporation	System for improving cardiac function by sealing a partitioning membrane within a ventricle
US9332993B2 (en)	2004-08-05	2016-05-10	Cardiokinetix, Inc.	Devices and methods for delivering an endocardial device
US9078660B2 (en)	2000-08-09	2015-07-14	Cardiokinetix, Inc.	Devices and methods for delivering an endocardial device
US10064696B2 (en)	2000-08-09	2018-09-04	Edwards Lifesciences Corporation	Devices and methods for delivering an endocardial device
US9332992B2 (en)	2004-08-05	2016-05-10	Cardiokinetix, Inc.	Method for making a laminar ventricular partitioning device
US7291331B1 (en)	2002-09-11	2007-11-06	La Jolla Institute For Allergy And Immunology	Methods of treating OX40 medicated recall immune responses
JP4753867B2 (ja) *	2003-04-15	2011-08-24	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	ヒトｉｌ−１８を含むコンジュゲートおよびその置換変異体
MXPA05013879A (es)	2003-06-18	2006-06-27	Genelux Corp	Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos.
US7288638B2 (en)	2003-10-10	2007-10-30	Bristol-Myers Squibb Company	Fully human antibodies against human 4-1BB
GB0417487D0 (en)	2004-08-05	2004-09-08	Novartis Ag	Organic compound
DK1931697T3 (da) *	2005-09-28	2010-11-08	Zymogenetics Inc	IL-17A og IL-17F-antagonister og fremgangsmåder til anvendelse af disse
TWI461436B (zh) *	2005-11-25	2014-11-21	Kyowa Hakko Kirin Co Ltd	人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
TW200732349A (en)	2005-12-16	2007-09-01	Genentech Inc	Anti-OX40L antibodies and methods using same
WO2007130724A2 (en) *	2006-02-06	2007-11-15	Northwind Ventures	Systems and methods for volume reduction
AU2008219666A1 (en) *	2007-02-27	2008-09-04	Genentech, Inc.	Antagonist OX40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
WO2008109379A1 (en) *	2007-03-02	2008-09-12	Mdrna, Inc.	Nucleic acid compounds for inhibiting il17a gene expression and uses thereof
PE20091174A1 (es)	2007-12-27	2009-08-03	Chugai Pharmaceutical Co Ltd	Formulacion liquida con contenido de alta concentracion de anticuerpo
EP2493417B1 (en)	2009-10-26	2017-06-21	Cardiokinetix, Inc.	Ventricular volume reduction
EP3372617B1 (en) *	2010-04-02	2024-07-24	Amunix Pharmaceuticals, Inc.	Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2013116682A1 (en)	2012-02-02	2013-08-08	Ensemble Therapeutics Corporation	Macrocyclic compounds for modulating il-17
EP2946014A2 (en) *	2013-01-17	2015-11-25	Moderna Therapeutics, Inc.	Signal-sensor polynucleotides for the alteration of cellular phenotypes
WO2016048802A1 (en)	2014-09-28	2016-03-31	Cardiokinetix, Inc.	Apparatuses for treating cardiac dysfunction
CN107949570A (zh) *	2015-06-30	2018-04-20	勃林格殷格翰国际有限公司	多特异性结合蛋白
EP3192805A1 (en) *	2016-01-15	2017-07-19	Humanitas Mirasole S.p.A.	Inhibitors of t cell activation or stimulation and uses thereof
US10898330B2 (en)	2017-03-28	2021-01-26	Edwards Lifesciences Corporation	Positioning, deploying, and retrieving implantable devices
CN111320691B (zh) *	2018-12-17	2022-04-05	程联胜	一种抗人4-1bb单克隆抗体及其应用
CN113234139A (zh) *	2020-04-17	2021-08-10	百奥赛图江苏基因生物技术有限公司	Tnfsf9基因人源化的非人动物及其构建方法和应用
CN113730388B (zh) *	2021-10-22	2024-06-21	浙江大学	辛酸钠在制备改善心肺复苏效果以及心肺复苏后多器官功能障碍的药物中的应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5457A (en)		1848-02-22		Behch-vise
US4737462A (en)	1982-10-19	1988-04-12	Cetus Corporation	Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en)	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
WO1986000991A1 (en)	1984-07-24	1986-02-13	Commonwealth Serum Laboratories Commission	Method for determining mimotopes
US4751180A (en)	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
US4935233A (en)	1985-12-02	1990-06-19	G. D. Searle And Company	Covalently linked polypeptide cell modulators
US5071972A (en)	1986-01-31	1991-12-10	Genetics Institute, Inc.	DNA sequences encoding novel thrombolytic proteins
WO1988001213A1 (en)	1986-08-18	1988-02-25	Clinical Technologies Associates, Inc.	Delivery systems for pharmacological agents
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5011912A (en)	1986-12-19	1991-04-30	Immunex Corporation	Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
DE3889853D1 (de)	1987-11-05	1994-07-07	Hybritech Inc	Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
US20060002904A9 (en) *	1988-11-07	2006-01-05	Kwon Byoung S	Receptor and related products and methods
US6362325B1 (en) *	1988-11-07	2002-03-26	Advanced Research And Technology Institute, Inc.	Murine 4-1BB gene
US6303121B1 (en) *	1992-07-30	2001-10-16	Advanced Research And Technology	Method of using human receptor protein 4-1BB
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5013556A (en)	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
DE69127627T2 (de)	1990-08-29	1998-02-19	Genpharm Int	Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5716805A (en)	1991-10-25	1998-02-10	Immunex Corporation	Methods of preparing soluble, oligomeric proteins
US5262522A (en)	1991-11-22	1993-11-16	Immunex Corporation	Receptor for oncostatin M and leukemia inhibitory factor
AU666388B2 (en)	1992-05-26	1996-02-08	Immunex Corporation	Novel cytokine that binds CD30
US5792451A (en)	1994-03-02	1998-08-11	Emisphere Technologies, Inc.	Oral drug delivery compositions and methods
ES2279508T3 (es)	1992-11-13	2007-08-16	Immunex Corporation	Ligando elk, una citoquina.
WO1994026290A1 (en) *	1993-05-07	1994-11-24	Immunex Corporation	Cytokine designated 4-1bb ligand and human receptor that binds thereto
US7211259B1 (en) *	1993-05-07	2007-05-01	Immunex Corporation	4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US6274711B1 (en) *	1993-06-14	2001-08-14	Inserm, Institut National De La Sante Et De La Recherche Medicale	Purified mammalian CTLA-8 antigens and related reagents
US5457035A (en)	1993-07-23	1995-10-10	Immunex Corporation	Cytokine which is a ligand for OX40
US5470952A (en)	1993-10-20	1995-11-28	Regeneron Pharmaceuticals, Inc.	CNTF and IL-6 antagonists
US5821332A (en)	1993-11-03	1998-10-13	The Board Of Trustees Of The Leland Stanford Junior University	Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en)	1994-02-10	2001-06-05	Board Of Trustees Of The Leland Stanford Junior University	Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
US6407059B1 (en)	1994-06-08	2002-06-18	Peptor Limited	Conformationally constrained backbone cyclized peptide analogs
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US6169073B1 (en)	1995-02-16	2001-01-02	Bayer Corporation	Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
US5877155A (en)	1995-03-17	1999-03-02	The Research Foundation Of State University Of New York	Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
CA2215394C (en)	1995-03-23	2011-04-26	Immunex Corporation	Il-17 receptor
ES2185770T3 (es) *	1995-04-08	2003-05-01	Lg Chemical Ltd	Anticuerpo monoclonal especifico para 4-1bb humano y linea celular que lo produce.
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6127977A (en)	1996-11-08	2000-10-03	Cohen; Nathan	Microstrip patch antenna with fractal structure
US5776731A (en)	1996-02-21	1998-07-07	Immunex Corporation	DNA encoding type-I interleukin-I receptor-like protein designated 2F1
AU728657B2 (en)	1996-03-18	2001-01-18	Board Of Regents, The University Of Texas System	Immunoglobulin-like domains with increased half-lives
US6060283A (en)	1996-06-27	2000-05-09	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Genomic DNA encoding human interleukin-18 (IL-18, interferon-γ inducing factor)
TW515843B (en)	1996-07-25	2003-01-01	Hayashibara Biochem Lab	Process for producing an active polypeptide inducing interferon-γ production
ES2326347T3 (es) *	1996-11-27	2009-10-07	Immunex Corporation	Metodo para regular la produccion de oxido nitrico.
US6087116A (en)	1997-03-12	2000-07-11	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Interleukin-18 (IL-18) receptor polypeptides and their uses
IL121860A0 (en)	1997-08-14	1998-02-22	Yeda Res & Dev	Interleukin-18 binding proteins their preparation and use
PT1047781E (pt)	1998-01-23	2004-11-30	Immunex Corp	Receptores de il-18
PT1059931E (pt) *	1998-07-15	2003-04-30	Merckle Gmbh	Utilizacao de cd137 para promover a proliferacao de monocitos perifericos
WO2000023094A2 (en)	1998-10-16	2000-04-27	Immunex Corporation	Methods of inhibiting platelet activation and recruitment
US6660843B1 (en)	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
KR20000034847A (ko) *	1998-11-17	2000-06-26	성재갑	인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
MXPA03003407A (es) *	2000-10-18	2004-05-04	Immunex Corp	Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17.
US20040028687A1 (en) *	2002-01-15	2004-02-12	Waelti Ernst Rudolf	Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
AU2003290059A1 (en)	2002-12-16	2004-07-09	Herbert Schwarz	Use of cd137 antagonists for the treatment of tumors

2003
- 2003-08-21 PL PL376536A patent/PL376536A1/pl not_active Application Discontinuation
- 2003-08-21 US US10/646,308 patent/US20040136992A1/en not_active Abandoned
- 2003-08-21 CA CA2496795A patent/CA2496795C/en not_active Expired - Lifetime
- 2003-08-21 JP JP2004532947A patent/JP2006508056A/ja active Pending
- 2003-08-21 EP EP03791726A patent/EP1545578A4/en not_active Withdrawn
- 2003-08-21 WO PCT/US2003/026354 patent/WO2004019866A2/en not_active Ceased
- 2003-08-21 AU AU2003259995A patent/AU2003259995B2/en not_active Expired
- 2003-08-21 MX MXPA05002219A patent/MXPA05002219A/es unknown
2012
- 2012-06-26 US US13/533,727 patent/US8529894B2/en not_active Expired - Fee Related
2013
- 2013-08-07 US US13/961,691 patent/US20130323258A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US8529894B2 (en)	2013-09-10
US20130323258A1 (en)	2013-12-05
EP1545578A2 (en)	2005-06-29
WO2004019866A2 (en)	2004-03-11
AU2003259995B2 (en)	2009-07-02
WO2004019866A3 (en)	2004-07-08
WO2004019866B1 (en)	2004-10-14
US20120263729A1 (en)	2012-10-18
CA2496795A1 (en)	2004-03-11
AU2003259995A1 (en)	2004-03-19
CA2496795C (en)	2014-06-03
JP2006508056A (ja)	2006-03-09
MXPA05002219A (es)	2005-07-05
EP1545578A4 (en)	2010-07-07
US20040136992A1 (en)	2004-07-15

Publication	Publication Date	Title
PL376536A1 (pl)	2006-01-09	Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego
EA200601776A1 (ru)	2007-04-27	Метадоновые композиции местного действия и способы их применения
WO2005034998A3 (en)	2005-08-11	Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
ATE539751T1 (de)	2012-01-15	Verwendung von brimonidine zur behandlung von stress assoziierten zuständen
TW200602048A (en)	2006-01-16	Diphenylimidazopyrimidine and -imidazole amines as inhibitors of β -secretase
TW200716208A (en)	2007-05-01	Modified and immediate release memantine bead formulation
WO2005012530A3 (en)	2005-05-12	Antagonists and agonists of ldcam and methods of use
MX2009004038A (es)	2009-08-24	Gel de diclofenaco.
TW200640475A (en)	2006-12-01	Cosmetic and cosmeceutical compositions for restoration of skin barrier function
IL166022A0 (en)	2006-01-15	Use of HMGB1 in the treatment of tissue damage and/or to promote tissue repair
DE60322436D1 (de)	2008-09-04	Verabreichung von capsaicinoiden
EA200700684A1 (ru)	2007-10-26	Полиаминные композиции
NO20073254L (no)	2007-08-23	Sammensetninger omfattende ornitin og fenylacetat eller fenylbutyrat for a behandle hepatisk encefalopati
PH12012501372B1 (en)	2018-09-21	Proteasome inhibitors and methods of using the same
EP3330252A3 (en)	2018-07-18	Isoprenyl compounds and methods thereof
MX2009006452A (es)	2009-08-12	Gel-crema que comprende al menos un retinoide y peroxido de benzoilo.
WO2005000331A3 (en)	2005-05-26	Compositions for the treatment and prevention of degenerative joint disorders
ATE409065T1 (de)	2008-10-15	Inhibitoren der 17 beta- hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
MX2009010895A (es)	2009-10-26	Ranolazina para aumentar la secrecion de insulina.
WO2004093995A3 (en)	2005-04-21	Use of antioxidants to treat bone loss disorders
WO2006116626A3 (en)	2006-12-21	Methods and compositions for treating pain
CY1110182T1 (el)	2015-01-14	Ιδεβενονη για τη θεραπεια των μυϊκων δυστροφιων
GB2431346B (en)	2010-01-27	A combination composition comprising paracetamol and ibuprofen
MY162518A (en)	2017-06-15	Proteasome inhibitors and methods of using the same
TW200509863A (en)	2005-03-16	Irradiation device for medical use

Legal Events

Date	Code	Title	Description
2011-04-29	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)